The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease

Paola De Filippi, Sabrina Ravaglia, Bruno Bembi, Alfredo Costa, Arrigo Moglia, Giovanni Piccolo, Alessandra Repetto, Andrea Dardis, Giuseppe Greco, Giovanni Ciana, Francesco Canevari, Cesare Danesino

Research output: Contribution to journalArticle

Abstract

The insertion/deletion polymorphism of angiotensin-converting enzyme may influence muscle properties. We examined whether Pompe disease clinical manifestations, which are known to be highly variable among late-onset patients, may be modulated by angiotensin-converting enzyme polymorphism. METHODS: We included 38 patients with late-onset Pompe disease, aged 44.6 ± 19.8 years. We compared the distribution of angiotensin-converting enzyme polymorphism according to demographic and disease parameters. RESULTS: The distribution of angiotensin-converting enzyme polymorphism was in line with the general population, with 16% of patients carrying the II genotype, 37% carrying the DD genotype, and the remaining patients with the ID genotype. The three groups did not differ in mean age, disease duration, Walton score, and other scores used to measure disease severity. The DD polymorphism was associated with earlier onset of disease (P = 0.041), higher creatine kinase levels at diagnosis (P = 0.024), presence of muscle pain (P = 0.014), and more severe rate of disease progression (P = 0.037, analysis of variance test for interaction). DISCUSSION: These findings suggest a potential role of angiotensin-converting enzyme polymorphism in modulating Pompe disease phenotype and prognosis.

Original languageEnglish
Pages (from-to)206-211
Number of pages6
JournalGenetics in Medicine
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Glycogen Storage Disease Type II
Peptidyl-Dipeptidase A
Genotype
Myalgia
Creatine Kinase
Disease Progression
Analysis of Variance
Demography
Phenotype
Muscles
Population

Keywords

  • ACE polymorphism
  • Genotype-phenotype correlation
  • Muscle properties
  • Pompe disease
  • Type II glycogenosis

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease. / De Filippi, Paola; Ravaglia, Sabrina; Bembi, Bruno; Costa, Alfredo; Moglia, Arrigo; Piccolo, Giovanni; Repetto, Alessandra; Dardis, Andrea; Greco, Giuseppe; Ciana, Giovanni; Canevari, Francesco; Danesino, Cesare.

In: Genetics in Medicine, Vol. 12, No. 4, 04.2010, p. 206-211.

Research output: Contribution to journalArticle

De Filippi, Paola ; Ravaglia, Sabrina ; Bembi, Bruno ; Costa, Alfredo ; Moglia, Arrigo ; Piccolo, Giovanni ; Repetto, Alessandra ; Dardis, Andrea ; Greco, Giuseppe ; Ciana, Giovanni ; Canevari, Francesco ; Danesino, Cesare. / The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease. In: Genetics in Medicine. 2010 ; Vol. 12, No. 4. pp. 206-211.
@article{a324f97c794d44df99a7e8b0323ce8e7,
title = "The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease",
abstract = "The insertion/deletion polymorphism of angiotensin-converting enzyme may influence muscle properties. We examined whether Pompe disease clinical manifestations, which are known to be highly variable among late-onset patients, may be modulated by angiotensin-converting enzyme polymorphism. METHODS: We included 38 patients with late-onset Pompe disease, aged 44.6 ± 19.8 years. We compared the distribution of angiotensin-converting enzyme polymorphism according to demographic and disease parameters. RESULTS: The distribution of angiotensin-converting enzyme polymorphism was in line with the general population, with 16{\%} of patients carrying the II genotype, 37{\%} carrying the DD genotype, and the remaining patients with the ID genotype. The three groups did not differ in mean age, disease duration, Walton score, and other scores used to measure disease severity. The DD polymorphism was associated with earlier onset of disease (P = 0.041), higher creatine kinase levels at diagnosis (P = 0.024), presence of muscle pain (P = 0.014), and more severe rate of disease progression (P = 0.037, analysis of variance test for interaction). DISCUSSION: These findings suggest a potential role of angiotensin-converting enzyme polymorphism in modulating Pompe disease phenotype and prognosis.",
keywords = "ACE polymorphism, Genotype-phenotype correlation, Muscle properties, Pompe disease, Type II glycogenosis",
author = "{De Filippi}, Paola and Sabrina Ravaglia and Bruno Bembi and Alfredo Costa and Arrigo Moglia and Giovanni Piccolo and Alessandra Repetto and Andrea Dardis and Giuseppe Greco and Giovanni Ciana and Francesco Canevari and Cesare Danesino",
year = "2010",
month = "4",
doi = "10.1097/GIM.0b013e3181d2900e",
language = "English",
volume = "12",
pages = "206--211",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease

AU - De Filippi, Paola

AU - Ravaglia, Sabrina

AU - Bembi, Bruno

AU - Costa, Alfredo

AU - Moglia, Arrigo

AU - Piccolo, Giovanni

AU - Repetto, Alessandra

AU - Dardis, Andrea

AU - Greco, Giuseppe

AU - Ciana, Giovanni

AU - Canevari, Francesco

AU - Danesino, Cesare

PY - 2010/4

Y1 - 2010/4

N2 - The insertion/deletion polymorphism of angiotensin-converting enzyme may influence muscle properties. We examined whether Pompe disease clinical manifestations, which are known to be highly variable among late-onset patients, may be modulated by angiotensin-converting enzyme polymorphism. METHODS: We included 38 patients with late-onset Pompe disease, aged 44.6 ± 19.8 years. We compared the distribution of angiotensin-converting enzyme polymorphism according to demographic and disease parameters. RESULTS: The distribution of angiotensin-converting enzyme polymorphism was in line with the general population, with 16% of patients carrying the II genotype, 37% carrying the DD genotype, and the remaining patients with the ID genotype. The three groups did not differ in mean age, disease duration, Walton score, and other scores used to measure disease severity. The DD polymorphism was associated with earlier onset of disease (P = 0.041), higher creatine kinase levels at diagnosis (P = 0.024), presence of muscle pain (P = 0.014), and more severe rate of disease progression (P = 0.037, analysis of variance test for interaction). DISCUSSION: These findings suggest a potential role of angiotensin-converting enzyme polymorphism in modulating Pompe disease phenotype and prognosis.

AB - The insertion/deletion polymorphism of angiotensin-converting enzyme may influence muscle properties. We examined whether Pompe disease clinical manifestations, which are known to be highly variable among late-onset patients, may be modulated by angiotensin-converting enzyme polymorphism. METHODS: We included 38 patients with late-onset Pompe disease, aged 44.6 ± 19.8 years. We compared the distribution of angiotensin-converting enzyme polymorphism according to demographic and disease parameters. RESULTS: The distribution of angiotensin-converting enzyme polymorphism was in line with the general population, with 16% of patients carrying the II genotype, 37% carrying the DD genotype, and the remaining patients with the ID genotype. The three groups did not differ in mean age, disease duration, Walton score, and other scores used to measure disease severity. The DD polymorphism was associated with earlier onset of disease (P = 0.041), higher creatine kinase levels at diagnosis (P = 0.024), presence of muscle pain (P = 0.014), and more severe rate of disease progression (P = 0.037, analysis of variance test for interaction). DISCUSSION: These findings suggest a potential role of angiotensin-converting enzyme polymorphism in modulating Pompe disease phenotype and prognosis.

KW - ACE polymorphism

KW - Genotype-phenotype correlation

KW - Muscle properties

KW - Pompe disease

KW - Type II glycogenosis

UR - http://www.scopus.com/inward/record.url?scp=77951498293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951498293&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e3181d2900e

DO - 10.1097/GIM.0b013e3181d2900e

M3 - Article

C2 - 20308911

AN - SCOPUS:77951498293

VL - 12

SP - 206

EP - 211

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 4

ER -